372 related articles for article (PubMed ID: 19636337)
1. Genetic polymorphism, linkage disequilibrium, haplotype structure and novel allele analysis of CYP2C19 and CYP2D6 in Han Chinese.
Zhou Q; Yu XM; Lin HB; Wang L; Yun QZ; Hu SN; Wang DM
Pharmacogenomics J; 2009 Dec; 9(6):380-94. PubMed ID: 19636337
[TBL] [Abstract][Full Text] [Related]
2. Differences in genotype and allele frequency distributions of polymorphic drug metabolizing enzymes CYP2C19 and CYP2D6 in mainland Chinese Mongolian, Hui and Han populations.
Yin SJ; Ni YB; Wang SM; Wang X; Lou YQ; Zhang GL
J Clin Pharm Ther; 2012 Jun; 37(3):364-9. PubMed ID: 21913948
[TBL] [Abstract][Full Text] [Related]
3. Allele and genotype frequencies of CYP3A4, CYP2C19, and CYP2D6 in Han, Uighur, Hui, and Mongolian Chinese populations.
Zuo LJ; Guo T; Xia DY; Jia LH
Genet Test Mol Biomarkers; 2012 Feb; 16(2):102-8. PubMed ID: 22224559
[TBL] [Abstract][Full Text] [Related]
4. Genetic polymorphism analysis of CYP2C19 in Chinese Han populations from different geographic areas of mainland China.
Chen L; Qin S; Xie J; Tang J; Yang L; Shen W; Zhao X; Du J; He G; Feng G; He L; Xing Q
Pharmacogenomics; 2008 Jun; 9(6):691-702. PubMed ID: 18518848
[TBL] [Abstract][Full Text] [Related]
5. Polymorphisms and phenotypic analysis of cytochrome P450 2D6 in the Tibetan population.
Jin TB; Ma LF; Zhang JY; Yuan DY; Sun Q; Zong TY; Geng TT; Cui YL; Kang LL; Chen C
Gene; 2013 Sep; 527(1):360-5. PubMed ID: 23644254
[TBL] [Abstract][Full Text] [Related]
6. Allele and genotype frequencies of CYP2C9, CYP2C19 and CYP2D6 in an Italian population.
Scordo MG; Caputi AP; D'Arrigo C; Fava G; Spina E
Pharmacol Res; 2004 Aug; 50(2):195-200. PubMed ID: 15177309
[TBL] [Abstract][Full Text] [Related]
7. Genetic polymorphisms of drug-metabolizing phase I enzymes CYP3A4, CYP2C9, CYP2C19 and CYP2D6 in Han, Uighur, Hui and Mongolian Chinese populations.
Zuo J; Xia D; Jia L; Guo T
Pharmazie; 2012 Jul; 67(7):639-44. PubMed ID: 22888523
[TBL] [Abstract][Full Text] [Related]
8. Pilot study for the characterization of pharmacogenetically relevant CYP2D6, CYP2C19 and ABCB1 gene polymorphisms in the Hungarian population.
Rideg O; Háber A; Botz L; Szücs F; Várnai R; Miseta A; Kovács GL
Cell Biochem Funct; 2011 Oct; 29(7):562-8. PubMed ID: 21826689
[TBL] [Abstract][Full Text] [Related]
9. Polymorphisms of CYP2C19 and CYP2D6 in Israeli ethnic groups.
Luo HR; Aloumanis V; Lin KM; Gurwitz D; Wan YJ
Am J Pharmacogenomics; 2004; 4(6):395-401. PubMed ID: 15651900
[TBL] [Abstract][Full Text] [Related]
10. Pharmacogenomics of CYP2A6, CYP2B6, CYP2C19, CYP2D6, CYP3A4, CYP3A5 and MDR1 in Vietnam.
Veiga MI; Asimus S; Ferreira PE; Martins JP; Cavaco I; Ribeiro V; Hai TN; Petzold MG; Björkman A; Ashton M; Gil JP
Eur J Clin Pharmacol; 2009 Apr; 65(4):355-63. PubMed ID: 18979093
[TBL] [Abstract][Full Text] [Related]
11. Distribution of CYP2D6 and CYP2C19 polymorphisms associated with poor metabolizer phenotype in five Amerindian groups and western Mestizos from Mexico.
Salazar-Flores J; Torres-Reyes LA; Martínez-Cortés G; Rubi-Castellanos R; Sosa-Macías M; Muñoz-Valle JF; González-González C; Ramírez A; Román R; Méndez JL; Barrera A; Torres A; Medina R; Rangel-Villalobos H
Genet Test Mol Biomarkers; 2012 Sep; 16(9):1098-104. PubMed ID: 22913530
[TBL] [Abstract][Full Text] [Related]
12. CYP2C9, CYP2C19 and CYP2D6 allele frequencies in the Ashkenazi Jewish population.
Scott SA; Edelmann L; Kornreich R; Erazo M; Desnick RJ
Pharmacogenomics; 2007 Jul; 8(7):721-30. PubMed ID: 18240905
[TBL] [Abstract][Full Text] [Related]
13. Polymorphisms of drug-metabolizing enzymes CYP2C9, CYP2C19, CYP2D6, CYP1A1, NAT2 and of P-glycoprotein in a Russian population.
Gaikovitch EA; Cascorbi I; Mrozikiewicz PM; Brockmöller J; Frötschl R; Köpke K; Gerloff T; Chernov JN; Roots I
Eur J Clin Pharmacol; 2003 Aug; 59(4):303-12. PubMed ID: 12879168
[TBL] [Abstract][Full Text] [Related]
14. Low frequency of defective alleles of cytochrome P450 enzymes 2C19 and 2D6 in the Turkish population.
Aynacioglu AS; Sachse C; Bozkurt A; Kortunay S; Nacak M; Schröder T; Kayaalp SO; Roots I; Brockmöller J
Clin Pharmacol Ther; 1999 Aug; 66(2):185-92. PubMed ID: 10460072
[TBL] [Abstract][Full Text] [Related]
15. Genetic polymorphisms of drug-metabolizing enzymes CYP2D6, CYP2C9, CYP2C19 and CYP3A5 in the Greek population.
Arvanitidis K; Ragia G; Iordanidou M; Kyriaki S; Xanthi A; Tavridou A; Manolopoulos VG
Fundam Clin Pharmacol; 2007 Aug; 21(4):419-26. PubMed ID: 17635181
[TBL] [Abstract][Full Text] [Related]
16. Allele and genotype frequencies of polymorphic cytochromes P4502D6, 2C19 and 2E1 in aborigines from western Australia.
Griese EU; Ilett KF; Kitteringham NR; Eichelbaum M; Powell H; Spargo RM; LeSouef PN; Musk AW; Minchin RF
Pharmacogenetics; 2001 Feb; 11(1):69-76. PubMed ID: 11207032
[TBL] [Abstract][Full Text] [Related]
17. Genetic polymorphisms of cytochrome P450 enzymes influence metabolism of the antidepressant escitalopram and treatment response.
Tsai MH; Lin KM; Hsiao MC; Shen WW; Lu ML; Tang HS; Fang CK; Wu CS; Lu SC; Liu SC; Chen CY; Liu YL
Pharmacogenomics; 2010 Apr; 11(4):537-46. PubMed ID: 20350136
[TBL] [Abstract][Full Text] [Related]
18. Association of genetic polymorphisms of CYP 2C19 with hypertension in a Chinese Han population.
Ma Y; Ni W; Zhu W; Xiong Y; Deng X
Blood Press; 2011 Jun; 20(3):166-70. PubMed ID: 21332417
[TBL] [Abstract][Full Text] [Related]
19. The effect of genetic polymorphisms of cytochrome P450 CYP2C9, CYP2C19, and CYP2D6 on drug-resistant epilepsy in Turkish children.
Seven M; Batar B; Unal S; Yesil G; Yuksel A; Guven M
Mol Diagn Ther; 2014 Apr; 18(2):229-36. PubMed ID: 24338437
[TBL] [Abstract][Full Text] [Related]
20. The high prevalence of the poor and ultrarapid metabolite alleles of CYP2D6, CYP2C9, CYP2C19, CYP3A4, and CYP3A5 in Taiwanese population.
Liou YH; Lin CT; Wu YJ; Wu LS
J Hum Genet; 2006; 51(10):857. PubMed ID: 16924387
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
